1. 105687210 一种含有呋塞米和螺内酯的复方降压药物组合制剂及其制备方法
CN
22.06.2016
A61K 31/585 Loading...
A61K 31/585
Loading...
201610042060.9
宁夏康亚药业有限公司
韩丽娟
A61K 31/585
Loading...
本发明公开了一种含有呋塞米和螺内酯的复方降压药物组合制剂及其制备方法。其中，该复方降压药物组合制剂包括片芯和包衣，片芯按照片芯总重量计包括如下组分：呋塞米10％～40％、螺内酯为20％～50％、增溶剂2％～4％、填充剂10％～60％、崩解剂4％～8％，润滑剂0.5％～1％和粘合剂0.1％～2％。
2. 105534938 一种吡贝地尔亲水凝胶膜控缓释制剂及其制备方法
CN
04.05.2016
A61K 9/28 Loading...
A61K 9/28
Loading...
201610043866.X
宁夏康亚药业有限公司
马健国
A61K 9/28
Loading...
本发明提供了一种吡贝地尔亲水凝胶膜控缓释制剂及其制备方法。该吡贝地尔缓释片含有亲水凝胶骨架材料、填充剂、润滑剂、粘合剂、缓释包衣材料，采用如下步骤制备而成：(1)将主药吡贝地尔微粉化；(2)将微粉化后的主药吡贝地尔与填充剂混合均匀，加入适量粘合剂，制粒，烘干，整粒；(3)将(2)中干颗粒与亲水凝胶骨架材料混合均匀后，加入润滑剂，混匀，压片；(4)取(3)中片芯置包衣锅中，以缓释包衣材料进行包衣，即得亲水凝胶膜控缓释片。该吡贝地尔缓释片采用亲水凝胶骨架材料和缓释包衣材料，不仅延缓了吡贝地尔的释放，使药物的释放更加稳定，提高药效。提高了病人的依从性，同时具有良好的体内外相关性。
3. 105213335 格列吡嗪片剂及其制备方法与应用
CN
06.01.2016
A61K 9/20 Loading...
A61K 9/20
Loading...
201510626347.1
宁夏康亚药业有限公司
李娟
A61K 9/20
Loading...
本发明公开了一种格列吡嗪片剂及其制备方法与应用。其中格林吡嗪片剂以重量百分含量计包括：颗粒粒径D50为50μm～100μm的格列吡嗪1％～5％，增溶剂1％～10％，填充剂50％～90％，崩解剂5％～15％，润滑剂0.1％～5％，以及2％～15％的粘合剂适量。其中，格列吡嗪优选为颗粒粒径D50为50μm～75μm的格列吡嗪。在本发明中通过将有效成分格列吡嗪微粉化，减小原料药格列吡嗪的粒径，同时增加增溶剂与格列吡嗪配合以提高药物释放度，从而提高生物利用度，进而提高产品质量。
4. 105147631 一种非诺贝酸片及其制备方法
CN
16.12.2015
A61K 9/20 Loading...
A61K 9/20
Loading...
201510628513.1
宁夏康亚药业有限公司
孙小惠
A61K 9/20
Loading...
本发明公开了一种非诺贝酸片及其制备方法。该非诺贝酸片由下列成分组成：非诺贝酸、填充剂、崩解剂、润滑剂、粘合剂适量。本发明的非诺贝酸片提高了非诺贝酸的溶出度，非诺贝酸在小肠区有较高的溶解度，因此增加了非诺贝酸的生物利用度，增加了其临床疗效。
5. 105130795 一种高纯度非诺贝酸原料药的制备方法
CN
09.12.2015
C07C 59/90 Loading...
C07C 59/90
Loading...
201510654061.4
宁夏康亚药业有限公司
李兆林
C07C 59/90
Loading...
本发明公开了一种非诺贝酸的制备方法，其以由结构式(I)表示的化合物为原料，与丙酮和氯仿在氢氧化钠为催化剂条件下，缩合反应得非诺贝酸，所述结构式(I)如下：？由结构式(I)表示的化合物为4ˊ-氯-4-羟基二苯甲酮。在本发明中通过结构式(I)的化合物与丙酮、氯仿在氢氧化钠催化下发生缩合反应，经氢氧化钠溶液水解，经2次调节pH值，制得非诺贝酸粗品。粗品经异丙醇重结晶，可得到高纯度的非诺贝酸。该方法合成的非诺贝酸产品收率较高，成本较低，操作简单，是一种适合工业化生产的方法。
6. 105061355 一种高纯度依帕司他的精制方法
CN
18.11.2015
C07D 277/36 Loading...
C07D 277/36
Loading...
201510588909.8
宁夏康亚药业有限公司
李栋
C07D 277/36
Loading...
本发明提供了一种高纯度依帕司他的精制方法,包括如下步骤：将依帕司他粗品加入到良溶剂中，于110℃下避光、搅拌回流溶解，溶解后，向其中加入不良溶剂，保温静置析晶、抽滤，滤饼用不良溶剂洗涤1次，60℃干燥，即得依帕司他终产品。所述依帕司他结构如下：本发明与现有技术相比，所用精制溶剂价廉易得，反应条件温和，生产成本低，污染小，并且操作简单，无需热滤，仅需一次重结晶，获得的依帕司他终产品纯度和收率高，提高了产品质量，并且适合大工业生产。
7. 104370886 艾普拉唑晶型及其制备方法和应用
CN
25.02.2015
C07D 401/14 Loading...
C07D 401/14
Loading...
201410657262.5
宁夏康亚药业有限公司
马攀勤
C07D 401/14
Loading...
本发明公开了艾普拉唑新M晶型及其制备方法和应用。本发明的艾普拉唑新M晶型，易于制备。本发明方法制备的艾普拉唑晶型纯度高，杂质含量低。本制备方法所需溶剂量少，生产成本低廉，操作简单，反应条件温和，容易控制。重现性好，可以稳定的获得目标产物晶型。
8. WO/2014/134922 MELOXICAM EYE DROPS AND PREPARATION METHOD AND USE THEREOF
WO
12.09.2014
A61K 31/5415 Loading...
A61K 31/5415
Loading...
PCT/CN2013/086042
KANGYA OF NINGXIA PHARMACEUTICALS CO., LTD.
YANG, Yajun
A61K 31/5415
Loading...
Disclosed is meloxicam eye drops and the preparation method and use thereof. The eye drops contain active ingredient meloxicam or a pharmaceutically acceptable salt thereof, a solubilizer, a stabilizer, a pH adjusting agent, an antimicrobial agent and an osmotic pressure adjusting agent, wherein the solubilizer is one of hydroxypropyl-β-cyclodextrin, sulfohydrocarbyl-β-cyclodextrin, and β-cyclodextrin or a mixture thereof, and the stabilizer is one of polymer povidone, sodium hyaluronate, and hypromellose or a mixture thereof.
9. 103772276 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4H)-喹啉基]乙酸的制备方法
CN
07.05.2014
C07D 215/233 Loading...
C07D 215/233
Loading...
201410001738.X
沈阳药科大学
王绍杰
C07D 215/233
Loading...
本发明中提供了一种2-[6-甲氧基-3-(2，3-二氯苯基)甲基-4-氧代-1，4-二氢-1(4H)-喹啉基]乙酸的制备方法，其包括以下步骤：以3-(4-甲氧基苯胺基)丙酸钠为原料，经氨基保护处理制备3-(N-保护基团-4-甲氧基苯胺基)丙酸，经傅克-酰基化反应制备N-保护基团-6-甲氧基-2，3-二氢喹啉酮，再经脱保护处理制备中间体6-甲氧基-2，3-二氢-4(1H)-喹啉酮；以中间体6-甲氧基-2，3-二氢-4(1H)-喹啉酮为原料，经N-烃化、水解、缩合反应制备目标产物。这种制备方法避免了大量使用多聚磷酸(PPA)，工艺环保，且更利于工业化生产。
10. 103739547 Synthesis method of 2-[6-methoxy-3-(2,3-dichlorophenyl)methyl-4-oxo-1,4-dihydro-1(4H)-quinolyl] acetic acid
CN
23.04.2014
C07D 215/20 Loading...
C07D 215/20
Loading...
201410001737.5
沈阳药科大学
王绍杰
C07D 215/20
Loading...
The invention provides a synthesis method of 2-[6-methoxy-3-(2,3-dichlorophenyl)methyl-4-oxo-1,4-dihydro-1(4H)-quinolyl] acetic acid. The method comprises the following steps: with 1-(4-methoxyphenyl)azacyclobutyl-2-one as a raw material, adding trifluoroacetic acid and performing a Friedel-Crafts acylation reaction by use of a catalyst; after the solvent is steamed out, adding a saturated aqueous solution of potassium hydroxide for neutralizing; performing suction filtration to obtain an intermediate 6-methoxy-2,3-dihydro-4(1H)-quinolinone; and with the intermediate 6-methoxy-2,3-dihydro-4(1H)-quinolinone as a raw material, performing N-hydrocarbonylation, hydrolysis and condensation reaction to synthesize the 2-[6-methoxy-3-(2,3-dichlorophenyl)methyl-4-oxo-1,4-dihydro-1(4H)-quinolyl] acetic acid. The synthesis method avoids a large dosage of polyphosphoric acid (PPA) and is environment-friendly in process and better for industrial production.
11. 103288799 兰索拉唑的合成方法及由该方法合成的兰索拉唑
CN
11.09.2013
C07D 401/12 Loading...
C07D 401/12
Loading...
201310068784.7
宁夏康亚药业有限公司
杨亚军
C07D 401/12
Loading...
本发明公开了一种兰索拉唑的合成方法，其以由结构式(I)表示的化合物为原料，用间氯过氧苯甲酸氧化所述由结构式(I)表示的化合物合成所述兰索拉唑，所述结构式(I)如下：。这种由结构式(I)表示的化合物为2-[2-[3-甲基-4-(2，2，2-三氟乙氧基)吡啶]甲基]硫-1H-苯并咪唑。在本发明中通过采用由结构式(I)表示的化合物为原料，用间氯过氧苯甲酸氧化所述由结构式(I)表示的化合物合成所述兰索拉唑，不但能够提高兰索拉唑的收率，而且还能够减少兰索拉唑产品中杂质的含量。同时该操作简单，反应条件温和，是一种经济适用的合成方法。
12. 103142463 Eye medicament composition as well as preparation method and application thereof
CN
12.06.2013
A61K 9/06 Loading...
A61K 9/06
Loading...
201310068780.9
宁夏康亚药业有限公司
杨亚军
A61K 9/06
Loading...
The invention discloses an eye medicament composition as well as a preparation method and an application thereof. The eye medicament composition comprises the following components in percentage by weight: 0.1-1.0% of gatifloxacin, 0.1-5.0% of gel substrate, 0.5-8% of an osmotic pressure regulator, 0.01-0.03% of a bacteriostat, 0.02-0.5% of a metal chelating agent, 1-10% of a clathration agent, 90-98% of water for injection and an appropriate quantity of a pH regulator. The gel substrate is added, so that the residence time of the eye medicament composition in the eyes can be effectively prolonged, enough time is provided for a medicament to come into play after being dropped into the eyes through corneas, the bioavailability is improved, the frequency of using the eye medicament composition is reduced, the compliance of a patient is improved, and the effectiveness of treatment is guaranteed. Meanwhile, an appropriate quantity of the metal chelating agent is added and used as a stabilizer, and the clathration agent is synergistically added, so that the problem of low stability of a gatifloxacin aqueous preparation is successfully solved.
13. 103110575 一种美洛昔康滴眼液及其制备方法和应用
CN
22.05.2013
A61K 9/08 Loading...
A61K 9/08
Loading...
201310072193.7
宁夏康亚药业有限公司
杨亚军
A61K 9/08
Loading...
本发明公开了一种美洛昔康滴眼液及其制备方法和应用，其特征在于：包括活性成分美洛昔康或其可药用的盐、增溶剂、稳定剂、pH调节剂、抑菌剂及渗透压调节剂；所述增溶剂为羟丙基-β-环糊精、磺汀基-β-环糊精、β-环糊精中的一种或其混合物；所述稳定剂为高分子聚合物聚维酮、透明质酸钠、羟丙甲纤维素中的一种或其混合物。其制备方法是将增溶剂溶于水中，在加热下，加入美洛昔康或其可药用盐，使其完全溶解后，依次加入其他辅料，搅拌至完全溶解、冷却至室温，调节pH值，补加注射用水至全量，微孔滤膜过滤，即得。增溶剂和稳定剂在增加美洛昔康溶解度使其达到用药要求的同时，显著提高美洛昔康滴眼液的稳定性，延长了滴眼液的储藏寿命和使用的安全性。
14. 103054872 美洛昔康药物组合物及其制备方法
CN
24.04.2013
A61K 31/5415 Loading...
A61K 31/5415
Loading...
201310025821.6
宁夏康亚药业有限公司
杨亚军
A61K 31/5415
Loading...
本发明公开了一种美洛昔康药物组合物及其制备方法。美洛昔康药物组合物按重量百分含量计包含以下组分：2％～10％的有效成分美洛昔康、70％～80％的填充剂、7％～11％的崩解剂、2％～5％的粘合剂、0.2％～0.8％的增溶剂、0.2％～5％的润滑剂，以及适量的溶剂。本发明所提供的美洛昔康的药物组合物合理的辅料选取及比例分配，使本发明所制得的美洛昔康片在体外溶出上具有明显提高。同时，本发明所提供的美洛昔康组合物通过湿法制粒的制备方法，制得的片剂片面外形美观、颗粒流动性好、耐磨性较强、压缩成形性好；通过对处方及工艺的优化，保障了药物在生产过程中的稳定性，提高了产品质量。
15. 103006607 一种兰索拉唑肠溶片及其制备方法
CN
03.04.2013
A61K 9/28 Loading...
A61K 9/28
Loading...
201210492151.4
宁夏康亚药业有限公司
杨亚军
A61K 9/28
Loading...
本发明公开了一种兰索拉唑肠溶片，包括兰索拉唑作为活性成分，稳定剂、抗氧化剂、填充剂、崩解剂、润滑剂和适量的粘合剂。本发明将兰索拉唑制成片剂用于治疗消化性溃疡，其特征在于处方中采用碱性稳定剂，在片剂内可形成一个弱碱性的微环境，阻断药物在其他辅料存在的条件下及酸性条件下的降解；在处方中加入抗氧化剂，阻断药物在空气中被氧化而降解，以此来保证药品的质量。在生产工艺中，通过采用将原料药和部分辅料微粉化，减小原料药粒径，提高药物的溶解度；通过包肠溶衣的工艺，避免药物在胃酸中降解，使药物靶向释放，从而提高生物利用度。通过对处方及工艺的优化，保障了药物在生产过程中的稳定性，提高了产品质量。
16. 103006606 吡贝地尔缓释片及其制备方法
CN
03.04.2013
A61K 9/22 Loading...
A61K 9/22
Loading...
201310004181.0
宁夏康亚药业有限公司
杨亚军
A61K 9/22
Loading...
本发明提供了一种吡贝地尔缓释片及其制备方法，该吡贝地尔缓释片的原料按重量组成百分比计包含：吡贝地尔10％-80％；骨架材料1％-70％；填充剂10％-80％；润滑剂0.1％-5％；粘合剂适量。该吡贝地尔缓释片提高了吡贝地尔的释放度，提高了药物的稳定性，使其克服了因血浆药物浓度的波动而使药物疗效下降等缺点，维持了长时间稳定的血药浓度，避免了由药物浓度波动刺激多巴胺受体产生的运动并发症，满足了多巴胺受体持续激活的需要，提高了病人的依从性，保证了其临床疗效。
17. 102961399 氯化钠滴眼液及其制备方法
CN
13.03.2013
A61K 9/08 Loading...
A61K 9/08
Loading...
201210492152.9
宁夏康亚药业有限公司
杨亚军
A61K 9/08
Loading...
本发明提供了一种含羟丙甲纤维素的氯化钠滴眼液及其制备方法，该滴眼液包含氯化钠、羟丙甲纤维素和注射用水，还可以添加抑菌剂和酸碱调节剂。本该滴眼液的处方和用量是：以100ml计，含有氯化钠0.45～0.75g，羟丙甲纤维素0.03～0.06g，pH缓冲体系，注射用水。本发明的滴眼液作用持久，治疗干眼症效果显著，安全，副作用小。
18. 102895210 改善了溶出度的非布司他片剂
CN
30.01.2013
A61K 9/32 Loading...
A61K 9/32
Loading...
201210414112.2
宁夏康亚药业有限公司
杨亚军
A61K 9/32
Loading...
本发明公开了一种非布司他片剂及其制备方法，该非布司他片剂包括片芯和包衣，片芯按照重量百分含量包括如下组分：非布司他5％-30％、填充剂15％-60％、崩解剂1％-20％、表面活性剂0.1％-5％、润滑剂0.1％-8％、粘合剂适量。该非布司他片剂通过在合理的比例范围内采用强效崩解剂，同时联合使用表面活性剂使难溶性药物非布司他溶出，进而增加非布司他的溶解度，提高其生物利用度。而且该非布司他片剂制备方法简单、质量可控、稳定性良好。
19. 102895209 非布司他片剂
CN
30.01.2013
A61K 9/32 Loading...
A61K 9/32
Loading...
201210414080.6
宁夏康亚药业有限公司
杨亚军
A61K 9/32
Loading...
本发明公开了一种非布司他片剂，该非布司他片剂包括片芯和包衣，片芯按照重量百分含量包括如下组分：非布司他5％-30％、填充剂15％-60％、崩解剂1％-20％、表面活性剂0.1％-5％、润滑剂0.1％-8％、粘合剂适量。该非布司他片剂通过在合理的比例范围内采用强效崩解剂，同时联合使用表面活性剂使难溶性药物非布司他溶出，进而增加非布司他的溶解度，提高其生物利用度。而且该非布司他片剂制备方法简单、质量可控、稳定性良好。
20. 102579440 Stable levamlodipine composition
CN
18.07.2012
A61K 31/4422 Loading...
A61K 31/4422
Loading...
201210093475.0
宁夏康亚药业有限公司
杨亚军
A61K 31/4422
Loading...
The invention relates to a stable levamlodipine medicinal composition, which comprises an active ingredient consisting of levamlodipine or a pharmaceutically-acceptable salt thereof, a stabilizer, a filler, a disintegrating agent and a lubricating agent. The stabilizer is one or a composition of two or more than two of calcium hydrophosphate, calcium phosphate, calcium sulfate, citric acid or sodium citrate. By selecting appropriate auxiliary materials, a weakly-acid micro environment is formed in a tablet, and degradation under the conditions of moisture, heat and light illumination is blocked, so that the stable quality of a medicament is ensured.
21. 102488665 非布司他片剂及其制备方法
CN
13.06.2012
A61K 9/20 Loading...
A61K 9/20
Loading...
201110419209.8
宁夏康亚药业有限公司
杨亚军
A61K 9/20
Loading...
本发明公开了一种非布司他片剂及其制备方法，该非布司他片剂包括片芯和包衣，片芯按照重量百分含量包括如下组分：非布司他5％-30％、填充剂15％-60％、崩解剂1％-20％、表面活性剂0.1％-5％、润滑剂0.1％-8％、粘合剂适量。该非布司他片剂通过在合理的比例范围内采用强效崩解剂，同时联合使用表面活性剂使难溶性药物非布司他溶出，进而增加非布司他的溶解度，提高其生物利用度。而且该非布司他片剂制备方法简单、质量可控、稳定性良好。
22. 102327263 复方降压药物组合物及复方降压片剂
CN
25.01.2012
A61K 31/4422 Loading...
A61K 31/4422
Loading...
201110187762.3
宁夏康亚药业有限公司
刘铮
A61K 31/4422
Loading...
本发明公开了一种复方降压药物组合物及复方降压片剂，复方降压药物组合物包括左旋氨氯地平或药学上可接受的盐与吲哒帕胺，其中，吲哒帕胺与左旋氨氯地平的重量比为1∶1.5～12。本发明新型复方降压制剂，利用药物之间的协调作用，提高降压效果，降压作用平稳，减少了副作用，具有优良的性价比，便于在人群中大量普及推广使用。本发明所提供的复方降压片剂稳定性良好，能够有效延长有效期。
23. 101880248 Synthetic reaction of calcium dobesilate hydrate
CN
10.11.2010
C07C 309/42 Loading...
C07C 309/42
Loading...
201010200151.3
Ningxia Kangya Pharmaceutical Co., Ltd.
Yang Yajun
C07C 309/42
Loading...
The invention relates to a synthesizing process of calcium dobesilate hydrate in pharmaceutical industry. Hydroquinone and concentrated sulfuric acid are directly sulfonated and then the sulfonated product in water solution state and calcium carbonate are neutralized to prepare the calcium dobesilate hydrate. In the synthesizing process, the operation is simplified, the industrialization cost is saved, the reaction conditions are mild, the product purity is high, the reaction end point is controllable, and the process is suitable for industrial mass production.
24. 101862364 Preparation method of traditional Chinese medicinal extract of Chinese angelica and red flower and series preparations thereof
CN
20.10.2010
A61K 36/286 Loading...
A61K 36/286
Loading...
201010127401.5
Ningxia Kangya Pharmaceutical Co., Ltd.
He Gang
A61K 36/286
Loading...
The invention relates to a preparation method of a traditional Chinese medicinal extract of Chinese angelica and red flower. The traditional Chinese medicinal extract is prepared by taking natural traditional Chinese herbal medicines of the red flower and the Chinese angelica as raw material medicines by the weight ratio of 1:0.5-1:5 and comprising the following steps of: (1) taking the red flower and the Chinese angelica and soaking with proper solvent; (2) respectively extracting 1-4 times with water by the ratio of 1:5-1:20 and decocting for 0.5-3 hours for each time; and (3) combining extraction liquid, decompressing and condensing to the volume equivalent to 1:0.5-1:4 of the crude medicine, and then pouring and filtering to obtain the traditional Chinese medicinal extract of the Chinese angelica and the red flower. The invention confirms the unique therapeutic effects of the Chinese angelica and the red flower on the aspect of treating cardiovascular and cerebrovascular diseases. Since the Chinese angelica and the red flower have remarkable advantages on improving and treating the cardiovascular and cerebrovascular diseases, the invention applies the Chinese angelica and the red flower in a combination way and prepared water extracts of the Chinese angelica and the red flower into certain preparations suitable for large industrial production so as to meet the medication requirements of mass patients.
25. 101735201 Preparation method of piribedil
CN
16.06.2010
C07D 405/12 Loading...
C07D 405/12
Loading...
200910117726.2
Ningxia Kangya Pharmaceutical Co., Ltd.
Ren Quanqing
C07D 405/12
Loading...
The invention relates to a preparation method of piribedil. The method is characterized in that piperidine is used as a starting raw material, and piperonyl chlorine is prepared through a Blanc reaction; in addition, 2-cloro pyridine is used as a starting raw material to carry out single alkylation on piperazine to obtain 1-(2-pyrimidyl)piperazine; and the prepared piperonyl chlorine and the 1-(2-pyrimidyl)piperazine are subjected to an N-alkylation reaction to obtain the piribedil. The invention has the advantages that the raw material piperidine has low price and is easy to obtain; the reaction condition is moderate, and reactions of all steps can be quickly carried out at lower temperature without high temperature, high pressure or special catalysts; the yield of products is higher; a purification method is simple; the purity is better (the purity content of HPLC is not lower than 99.8 percent), and the like, thus the method is a route which has simple operation, higher yield, lower cost and stable quality and is suitable for industrial production.
26. 101564424 Common lamiophlomis root chewable tablet and preparation thereof
CN
28.10.2009
A61K 9/20 Loading...
A61K 9/20
Loading...
200910117296.4
Ningxia Kangya Pharmaceutical Co., Ltd.
Yang Yajun
A61K 9/20
Loading...
The invention relates to a common lamiophlomis root chewable tablet and preparation thereof. The chewable tablet is a novel dosage form of common lamiophlomis root prepared from a common lamiophlomis root, a filler, a corrigent, a lubricant, and a binder. It is proposed that the medicament is made into chewable tablets with consideration on inconvenience in taking the medicament by patient and fear of medicament admission of the aged and the children. Comparing with the ordinary tablets and capsules, the chewable tablet can be chewed and swallowed, having great disintegrating degree. The chewable tablet is not only beneficial to absorption of effective ingredients, shortening affecting time, but also better in mouth feeling comparing with ordinary tablet and capsule, making the aged and the children eager to take, thus adaptability of patient in taking the medicament is enhanced. And the chewable tablet is suitable for large scale production because of no special requirement for the apparatus.
27. 101497589 Method for synthesizing 2-(3-cyano-4- isobutoxy phenyl)-4-methyl-carboxylate
CN
05.08.2009
C07D 277/56 Loading...
C07D 277/56
Loading...
200910010466.9
Shenyang Pharmaceutical University
Wang Shaojie
C07D 277/56
Loading...
The invention belongs to the technical field of medicine, and relates to a method for synthesizing 2-(3-cyano-4-isobutoxy phenyl)-4-methyl-5-thiazole formic acid. The method comprises that: 4-hydroxyl cyanobenzene is used as a raw material, and subjected to iodination, hydrocarbylation and cyanation to obtain an intermediate of 4-isobutoxy-1,3-benzene dinitrile, the intermediate reacts with sodium bisulfide and anhydrous magnesium chloride to obtain a key intermediate of 3-cyano-4-isobutoxy phenyl thioformamide, and the 3-cyano group-4-isobutoxy phenyl thioformamide is subjected to cyclization and hydrolysis reaction to obtain the 2-(3-cyano-4-isobutoxy phenyl)-4-methyl-5-thiazole formic acid. The method has the advantages of easily obtained materials, simple and convenient operation, high yield, low cost and suitability for industrialized production.
28. 101167726 Rosiglitazone maleate dispersible tablet and preparation method thereof
CN
30.04.2008
A61K 31/4439 Loading...
A61K 31/4439
Loading...
200710181728.9
Ningxia Kangya Pharmacy Group Co., Ltd.
Yang Yajun
A61K 31/4439
Loading...
The invention discloses a new preparation of rosiglitazone maleate: rosiglitazone maleate tablets and a process for preparation, which is made of rosiglitazone maleate 1-20%, disintegration agent 1-70%, bulking agent 10-90%, and lubricating agent 0.1-2%. The invention of rosiglitazone maleate tablets have the advantages of novel preparation, convenient intaking, excellent absorbability, less stimulation on the gastrointestinal tract, stable quality for long-term storage, and especially adapt to the old and the patient with deglutition difficulties. The preparation technique is simple and has no particular requirement on equipment, which adapts to large-scale production. The invention can be used to prepare the medicament for the treatment of II-type diabetes mellitus.
29. 101058558 4-Oxy-1(4H)-quinoline carboxylic acids compound and composition with aldose reductase inhibition activity and preparation method thereof
CN
24.10.2007
C07D 215/233 Loading...
C07D 215/233
Loading...
200710011464.2
Shenyang Pharmaceutical University
Wang Shaojie
C07D 215/233
Loading...
The invention discloses a 4-oxy-1 (4H)-quinoline carboxyl compound and derivant with structure as general formula I and II, which provides tautomeric body, medicinal salt, medicinal solvent and medicinal composition and preparing method. The invention can treat diabetic cardiovascular and cerebrovascular disease, diabetic nephrosis, diabetic nerve pathology and complication.
30. 1985801 Benzydalysine eye drop and its preparing method
CN
27.06.2007
A61K 9/00 Loading...
A61K 9/00
Loading...
200610105166.5
Kangya Pharmaceutical Industry Co., Ltd., Ningxia
Zhang Zhihua
A61K 9/00
Loading...
The present invention is a kind of benzydalysine eye drop, which is prepared with benzydalysine as main medicine component, and thickener, salt buffer, isosmotic agent, bacteriostat, stabilizer and water for injection. The benzydalysine eye drop of the present invention has stable quality, no irritation and other advantages.
31. 1943564 Indapamide slow release tablet and its preparing method
CN
11.04.2007
A61K 9/20 Loading...
A61K 9/20
Loading...
200610143058.7
Kangya Pharmaceutical Co., Ltd., Ningxia
Zhang Zhihua
A61K 9/20
Loading...
The invention relates to a indapamide retard tablet and its preparation process, said retard tablet comprising indapamide, bone material, filler and lubricant, in each said tablet containing controllable 0.5-1.5mg( each tablet containing 0.15 g. or 150g/1000 tablet ).

